🔥Telegram İfşa

#InViaggioconlaRicerca🇺🇲: grazie a una borsa iCARE-2 sostenuta da AIRC e dalla UE, Simone Lubrano si trova al Moores Cancer Center dell’Università della California a San Diego per studiare il melanoma uveale, un tumore dell'occhio ancora poco curabile ➡ bit.ly/2XaL3Ac

Farewell cake for Sally and Simone Simone Lubrano ! Many many thanks for your contributions to our lab! It was a privilege working with you! Celebrating your accomplishments, and your many amazing discoveries to come. Thanks! Cheers!

Thanks GutkindLab for this amazing experience, such a great environment, and wonderful/talented scientists. Looking forward to continuing our collaboration!

All students of the PhD course in Science of Drug and Bioactive Substance are welcome to attend the seminar. Thank you!

Now, Simone Lubrano from GutkindLab's lab UC San Diego Health Moores Cancer Center is telling us about drug combinations to overcome resistance to BRAF/MEK inhibitors and immunotherapy in #melanoma #TraineeMeeting Society For Melanoma Research

It’s been such an honor to present at the main session of the SMR Society For Melanoma Research Conference in New Orleans 🇺🇸, to be recognized for one of the top oral trainee presentations, and to discuss our results with some of the world’s leading Melanoma Scientists. #Melanoma #Resistance

I invite you to attend the Seminar I will be giving on Thursday, December 12 at 11:30 a.m. at the Scuola Normale Superiore, Pisa, on our latest Research on Strategies to Overcome Therapy Resistance in Cutaneous Melanoma.

Melanoma resists BRAF-targeted treatments, but combining avutometinib with FAK inhibitors may help overcome it. MCC's AD of Basic Science, GutkindLab, explores this in a recent Cancer Cell publication: bit.ly/4bm57Ut.

Online Now: FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma dlvr.it/TJDjXw

✍️#Melanoma Combination therapy overcomes treatment resistance in #melanoma 📢Interview with GutkindLab Simone Lubrano (UC San Diego). 👉bioworld.com/articles/71755… Researchers uncover a key mechanism underlying the treatment resistance of melanoma with the BRAF V600E mutation.